Drug Trial Radar · NCT01959243
Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants
Last checked: Nov 19, 2026Latest source record: Oct 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
507
Actual
Start
Feb 22, 2014
Primary completion
Apr 23, 2014
Study completion Jun 23, 2014
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- Collaborators
- ORA, Inc.
- First posted
- Oct 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants. At least 51% of participants will be 40 years of age or older.
Conditions
- Hyperemia
Interventions
Brimonidine TartrateDrug
Ophthalmic solution to be applied as directed.
VehicleDrug
Ophthalmic solution to be applied as directed.
Sodium FluoresceinDrug
For use as needed during the study for evaluating corneal damage.
Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USPDrug
For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline up to Day 29
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Bausch Site 3
Phoenix, Arizona
Bausch Site 4
Havre de Grace, Maryland
Bausch Site 1
Andover, Massachusetts
Bausch Site 2
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.